NCT07442721 Sacral ESPB vs. PENG Block for Hip Hemiarthroplasty Analgesia
| NCT ID | NCT07442721 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fayoum University Hospital |
| Condition | Hip Arthroplasty |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-02-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sacral erector spinae plane block(S-ESPB) has been recently described. Case reports are showing that it is useful in various types of surgery. In case presentations, it has been reported as effective in providing analgesia in the posterior branches of the sacral nerves in pilonidal sinus surgery, in the treatment of radicular pain at the L5 - S1 level, after a sex reassignment operation and hypospadias surgery, and its use in combination with lumbar ESPB for analgesia was reported after hip prosthesis surgery . Described in 2018, pericapsular nerve group (PENG) block selectively targets the articular branches of the femoral and accessory obturator nerves thereby providing potential motorsparing analgesia for hip surgery . Recent studies found that PENG block targets the articular branches of the femoral and accessory obturator nerves, only anesthetizes the anterior hip joint sparing posterior part , as well as there was a motor impairment after block which is from local anesthetic (LA) diffusion to the femoral nerve . Motor-sparing regional anesthesia techniques have emerged as a safer alternative, balancing effective pain relief with the preservation of quadriceps function . These techniques align with Enhanced Recovery After Surgery (ERAS) protocols, which emphasize multimodal pain control, opioid minimization, and early mobility to reduce complications such as venous thromboembolism (VTE) and postoperative pneumonia .
Eligibility Criteria
Inclusion Criteria: * Patients with ages from 50 to 90 years of either gender, with diagnosis of intracapsular neck of femur fracture scheduled for elective hip hemiarthroplasty • Patients with an American Society of Anesthesiologists (ASA) physical status I to III. Exclusion Criteria: * • Patient refusal. * Allergy to local anesthetics and patient with infection at the injection site of block * Patient with contraindication to spinal anesthesia. * Coagulopathy as INR≥1.5 or platelets ≤80\*103 / microliter) * Patients with body mass index\>35 kg / m2 * Patients with peripheral neuropathy or diabetic neuropathy * Patients receiving opioids for chronic analgesic therapy (cancer, addiction). * Cognitive impairment preventing pain scoring. * Chronic renal failure requiring dose modification. * Bilateral hip fracture or previous ipsilateral hip surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07442721 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 90 Years, studying Hip Arthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07442721 currently recruiting?
Yes, NCT07442721 is actively recruiting participants. Contact the research team at sar15@fayoum.edu.eg for enrollment information.
Where is the NCT07442721 trial being conducted?
This trial is being conducted at El Fayoum Qesm, Egypt.
Who is sponsoring the NCT07442721 clinical trial?
NCT07442721 is sponsored by Fayoum University Hospital. The trial plans to enroll 80 participants.